RESUMO
Drug resistance in Plasmodium falciparum requires that new drugs must be developed. Plants are a potential source for drug discovery and development. Two plants that used to treat febrile illnesses in Nigeria were tested for in vitro and in vivo antimalarial activity and cytotoxicity in cancer cell lines. Methanol, hexane, and ethyl acetate leaf extracts of Ficus thonningii and Lophira alata were active in in vitro assays against P. falciparum NF54 (sensitive) and K1 (multiresistant) strains. Hexane extracts of F. thonningii and L. alata were the most effective extracts in in vitro assays with IC50 of 2.7 ± 1.6 µg/mL and 2.5 ± 0.3 µg/mL for NF54 and 10.4 ± 1.6 µg/mL and 2.5 ± 2.1 µg/mL for K1 strain. All extracts were nontoxic in cytotoxicity assays against KB human cell line with IC50 of over 20 µg/mL, demonstrating selectivity against P. falciparum. In vivo analysis shows that hexane extracts of both plants reduced parasitaemia. At the maximum dose tested, L. alata had a 74.4% reduction of parasitaemia while F. thonningii had a reduction of 84.5%, both extracts prolonged animal survival in mice infected with P. berghei NK65 when compared with vehicle treated controls. The antiplasmodial activity observed justifies the use of both plants in treating febrile conditions.
RESUMO
We report two improved assays for in vitro and in vivo screening of chemicals with potential anti-malarial activity against the blood stages of the rodent malaria parasite Plasmodiumberghei. These assays are based on the determination of luciferase activity (luminescence) in small blood samples containing transgenic blood stage parasites that express luciferase under the control of a promoter that is either schizont-specific (ama-1) or constitutive (eef1alphaa). Assay 1, the in vitro drug luminescence (ITDL) assay, measured the success of schizont maturation in the presence of candidate drugs quantifying luciferase activity in mature schizonts only (ama-1 promoter). The ITDL assay generated drug-inhibition curves and EC(50) values comparable to those obtained with standard in vitro drug-susceptibility assays. The second assay, the in vivo drug-luminescence (IVDL) assay, measured parasite growth in vivo in a standard 4-day suppressive drug test, monitored by measuring the constitutive luciferase activity of circulating parasites (eef1alphaa promoter). The IVDL assay generates growth-curves that are identical to those obtained by manual counting of parasites in Giemsa-stained smears. The reading of luminescence assays is rapid, requires a minimal number of handling steps and no experience with parasite morphology or handling fluorescence-activated cell sorters, produces no radioactive waste and test-plates can be stored for prolonged periods before processing. Both tests are suitable for use in larger-scale in vitro and in vivo screening of drugs. The standard methodology of anti-malarial drug screening and validation, which includes testing in rodent models of malaria, can be improved by the incorporation of such assays.
Assuntos
Antimaláricos/farmacologia , Luciferases/sangue , Malária/parasitologia , Parasitemia/diagnóstico , Plasmodium berghei/enzimologia , Animais , Animais Geneticamente Modificados , Luciferases/genética , Malária/tratamento farmacológico , Camundongos , Plasmodium berghei/genéticaRESUMO
Twenty plants identified and selected from Southwest and Middle belt Nigerian antimalarial ethnopharmacology were evaluated for in vitro cytotoxicity using the brine shrimp lethality assay. The methanol extracts of 20 plant samples from 11 plant families were subjected to the assay. Of the studied plants, Lippia multiflora and Morinda lucida bark were found to be cytotoxic, with LC(50) values of 1.1 and 2.6 microg/ml, respectively. The least toxic plant extract was Bridelia micrantha (LC(50) value >9.0 x 10(6) microg/ml). Most of the plants were found to be relatively non-toxic.